The Lancet
Study
May 2022
Patients and professionals
Two trials testing risankizumab (Skyrizi) drips to bring active Crohn's under control, including in people for whom other biologics had failed. Risankizumab led to more remissions, and more improvement seen on camera tests of the bowel, at 12 weeks than placebo, and was generally well tolerated.
Topics
Biologics and newer medicines
Jargon explained
induction
phase 3 trial
endoscopic response
Crohn's & Colitis UK
Web page
Jul 2026
For patients
Explains how new IBD medicines move from lab testing through clinical trials to licensing, and describes medicines currently in late-stage testing.
Topics
Research
Medicines
Jargon explained
clinical trial
licensing
phase 3
The Lancet
Study
Dec 2017
Patients and professionals
CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.
Topics
Monitoring
Biologics and newer medicines
Research
Jargon explained
tight control
faecal calprotectin
CRP
mucosal healing
treat to target
NHS
Web page
Dec 2022
For patients
The NHS explains what a clinical trial is and how to find one. It suggests asking your doctor or a patient organisation, and points to the Be Part of Research website, where you can search UK studies and contact researchers.
Topics
Research
Jargon explained
clinical trial
randomised
US National Library of Medicine
Tool
Patients and professionals
The largest worldwide database of clinical studies, run by the US government. It includes many trials running at UK hospitals, often drug-company trials of new Crohn's medicines. Each record lists the study's aim, who can join and where.
Topics
Research
Jargon explained
clinical trial
eligibility criteria
trial registry
NCT number
NIHR
Tool
For patients
The NHS research service's search tool for finding health studies to take part in across the UK. Searching for Crohn's disease lists studies currently recruiting, with who can join and where. A good first stop if you want to volunteer for a trial.
Topics
Research
Jargon explained
clinical trial
recruiting
The Lancet
Systematic review
Dec 2017
For professionals
A review of population studies from around the world. In Western countries the number of new cases is levelling off but more than 0.3% of people now live with IBD. In newly industrialised countries in Asia, Africa and South America, new cases are rising quickly as lifestyles become more Western.
Topics
About Crohn's disease
Research
Jargon explained
systematic review
incidence
prevalence
population-based study
New England Journal of Medicine
Study
Apr 2010
Patients and professionals
A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.
Topics
Biologics and newer medicines
Immunosuppressants
Research
Jargon explained
combination therapy
steroid-free remission
mucosal healing
randomised controlled trial
ISRCTN
Tool
Patients and professionals
A WHO-recognised registry where UK and international studies are recorded before they start, with their aims and progress. You can search it free for Crohn's studies, including UK trials such as PROFILE. Records are written for researchers, so they can be technical.
Topics
Research
Jargon explained
trial registry
study protocol
ISRCTN number
Gastroenterology
Study
Jan 2007
Patients and professionals
The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.
Topics
Biologics and newer medicines
Jargon explained
maintenance
remission
CDAI
placebo
The Lancet
Study
May 2002
Patients and professionals
This trial asked whether people who improve after a first dose of infliximab should keep having it. Those given regular doses every 8 weeks were more likely to be in remission at 30 and 54 weeks, more likely to come off steroids, and stayed well for longer than those who stopped. Serious infections were no more common. It set the pattern of regular, ongoing infliximab treatment.
Topics
Biologics and newer medicines
Research
Jargon explained
maintenance therapy
remission
placebo
Cochrane
Systematic review
Apr 2020
Patients and professionals
A Cochrane review of 14 studies, covering both drug and non-drug treatments such as exercise and psychological approaches, for fatigue in IBD. The reviewers concluded the evidence is too uncertain to say which treatments work and called for trials designed specifically around fatigue.
Topics
Fatigue
Research
Jargon explained
fatigue
systematic review